Loading...
Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra
Following the results of the TAX-327 study, questions have been raised as to whether administering chemotherapy to men with prostate cancer before symptomatic disease progression when receiving standard hormonal treatment can improve the duration and quality of patient survival. The GETUG-AFU-15 and...
Na minha lista:
| Udgivet i: | Ann Oncol |
|---|---|
| Main Authors: | , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Oxford University Press
2015
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4511224/ https://ncbi.nlm.nih.gov/pubmed/26002607 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdv245 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|